- Home
- APH vs REGN Comparison
APH vs REGN Comparison
Compare APH & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APH
- REGN
- Stock Information
- Founded
- APH 1932
- REGN 1988
- Country
- APH United States
- REGN United States
- Employees
- APH N/A
- REGN N/A
- Industry
- APH Electrical Products
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- APH Technology
- REGN Health Care
- Exchange
- APH Nasdaq
- REGN Nasdaq
- Market Cap
- APH 76.1B
- REGN 63.4B
- IPO Year
- APH 1991
- REGN 1991
- Fundamental
- Price
- APH $80.86
- REGN $527.78
- Analyst Decision
- APH Buy
- REGN Buy
- Analyst Count
- APH 13
- REGN 23
- Target Price
- APH $79.38
- REGN $907.39
- AVG Volume (30 Days)
- APH 8.1M
- REGN 1.2M
- Earning Date
- APH 04-23-2025
- REGN 04-29-2025
- Dividend Yield
- APH 0.82%
- REGN 0.33%
- EPS Growth
- APH 25.95
- REGN 16.49
- EPS
- APH 2.06
- REGN 39.43
- Revenue
- APH $16,777,400,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- APH $23.57
- REGN $2.38
- Revenue Next Year
- APH $8.38
- REGN $7.65
- P/E Ratio
- APH $39.26
- REGN $13.39
- Revenue Growth
- APH 30.70
- REGN 7.52
- 52 Week Low
- APH $54.77
- REGN $525.99
- 52 Week High
- APH $81.82
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- APH 71.98
- REGN 35.08
- Support Level
- APH $79.10
- REGN $520.50
- Resistance Level
- APH $81.82
- REGN $615.61
- Average True Range (ATR)
- APH 2.25
- REGN 22.65
- MACD
- APH 0.67
- REGN -2.54
- Stochastic Oscillator
- APH 94.54
- REGN 7.65
About APH Amphenol Corporation
Amphenol Corp is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).